Highlights and Quick Summary
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical 10Y Operating Income Growth (CAGR) of Phathom Pharmaceuticals, Inc.Most recent 10Y Operating Income Growth (CAGR)of PHAT including historical data for past 10 years.
Interactive Chart of 10Y Operating Income Growth (CAGR) of Phathom Pharmaceuticals, Inc.
Business Profile of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.